OPF-310 encapsulated porcine islets
Otsuka Pharmaceutical Factory
First-in-human xenotransplant program using encapsulated neonatal pig islet cells for adults with unstable T1D and repeated severe hypoglycemia despite closed-loop therapy. It is a bold supply-and-protection strategy, but still phase 1/2 with no peer-reviewed human efficacy results.
The scorecard
The central promise is protective encapsulation of porcine islets, aiming to avoid systemic immunosuppression; clinical proof is still pending.[2]
The trial measures efficacy, but no peer-reviewed insulin-independence or C-peptide outcomes are posted yet.[1]
Porcine islets could solve supply, but long-term survival, fibrosis resistance and glucose-responsive function in humans are unanswered.[1]
This is a transplanted combination product, not a simple infusion or drug; the exact implant burden matters and remains specialist-care only.[1]
First study is limited to ages 35-65 with unstable T1D and repeated severe hypoglycemia despite closed-loop therapy.[1]
The full picture
OPF-310 is unusual because it attacks two bottlenecks at once: cell supply and immune protection. Human donor islets are scarce; pig islets are potentially scalable. But xenotransplantation only becomes broadly useful if the encapsulation device protects cells from immune attack and fibrosis while still letting oxygen, glucose and insulin move fast enough. The current trial is exactly the right first step: unstable, high-risk T1D with severe hypoglycemia despite closed-loop therapy. It is not yet a proven cure.
Coming soon
ETA · Phase 1/2 recruiting; primary completion estimated 2027
Sources
- [1]OPF-310 encapsulated porcine islet cells for xenotransplantation (NCT06575426) · registry
- [2]Spotlight on OPF-310: a porcine-derived cell therapy in clinical trials · news · 2026-02-01
- [3]New T1D Practical Cure Trial Uses Pig Islets · news · 2025-08-07